DELUSION and Abilify


DELUSION Symptoms and Causes

Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with psychoses lose touch with reality. Two of the main symptoms are Delusions and hallucinations. Delusions are false beliefs, such as thinking that someone is plotting against you or that the TV is sending you secret messages. Hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there.

Schizophrenia is one type of psychotic disorder. People with bipolar disorder may also have psychotic symptoms. Other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke.

Treatment depends on the cause of the psychosis. It might involve drugs to control symptoms and talk therapy. Hospitalization is an option for serious cases where a person might be dangerous to himself or others.

Check out the latest treatments for DELUSION

DELUSION treatment research studies

Abilify clinical trials, surveys and public health registries

Find Drug Side Effect reports

Abilify Side Effects

Weight Increased (762)
Tremor (544)
Tardive Dyskinesia (527)
Insomnia (486)
Pregnancy (435)
Dyskinesia (400)
Dizziness (324)
Somnolence (323)
Nausea (313)
Restlessness (308)
Headache (296)
Fatigue (289)
Psychotic Disorder (287)
Akathisia (286)
Anxiety (282)
Agitation (257)
Vomiting (254)
Convulsion (243)
Delusion (233)
Blood Glucose Increased (228)
Depression (192)
Dystonia (189)
Feeling Abnormal (188)
Vision Blurred (185)
Suicidal Ideation (179)
Death (178)
Mania (178)
Hallucination (176)
Aggression (174)
Neuroleptic Malignant Syndrome (169)
Fall (169)
Confusional State (167)
Weight Decreased (150)
Extrapyramidal Disorder (140)
Dyspnoea (136)
Hallucination, Auditory (136)
Schizophrenia (135)
Gait Disturbance (135)
Abnormal Behaviour (135)
Muscle Spasms (133)
Suicide Attempt (131)
Loss Of Consciousness (128)
Hyperhidrosis (125)
Musculoskeletal Stiffness (123)
Dysphagia (123)
Asthenia (121)
Blood Creatine Phosphokinase Increased (110)
Oedema Peripheral (109)
Completed Suicide (108)
Irritability (105)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

DELUSION Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions
Conditions: Schizophrenia;   Schizophreniform Disorder
Interventions: Drug: D-Cycloserine;   Drug: Placebo;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Change in Psychotic Symptoms Rating Scale-Delusions (PSYRATS-D);   Change in Logical Memory Test-WMS-III;   Change in Alternate Beliefs Exercise (ABE)
2 Unknown  Using D-cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia
Condition: Schizophrenia
Interventions: Drug: D-cycloserine;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Total Delusion score as rated by the Scale for the Assessment of Positive Symptoms (SAPS);   Cognitive flexibility, as defined by number of alternative explanations generated in response to neutral, negative, and Delusion-specific stimuli;   Predictors of response to D-cycloserine facilitation of CBT for Delusions in baseline characteristics;   Psychotic Rating Scales (PSYRATS);   Beck Cognitive Insight Scale (BCIS);   Bead task measuring probabilistic reasoning;   Affective salience task;   Select items from the Maudsley Assessment of Delusions Scale
3 Not yet recruiting Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial
Condition: Paranoia in People With Schizophrenia-spectrum Diagnosis
Interventions: Other: Anxiety intervention;   Other: Reasoning intervention
Outcome Measure: Green Paranoid Thoughts Scale
4 Unknown  Trial of Cognitive Behavioral Therapy for Schizophrenia
Conditions: Schizophrenia;   Schizoaffective Disorder;   Delusional Disorder
Intervention: Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Positive and Negative Syndrome Scale (PANSS)before and after treatment and at 1-year-follow-up;   Depression before and after treatment and at 1-year-follow-up;   Dysfunctional Attitudes before and after treatment and at 1-year-follow-up;   Cognitive biases (jumping to conclusions, attribution, theory of mind) before and after treatment
5 Recruiting Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
Conditions: Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder;   Delusional Disorder;   Psychotic Disorder
Intervention: Drug: Risperidone/Olanzapine and PET scans
Outcome Measures: Occupancy of risperidone/olanzapine at the dopamine D2 receptor;   Tolerability of 40 % antipsychotic dose reduction and its relation to the % change in occupancy following dose reduction;   Relationship between plasma concentration of risperidone and its active metabolite, 9-OH-risperidone(or olanzapine) and dopamine D2 receptor occupancy in older patients, in comparison to historic young controls.
6 Unknown  Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis
Conditions: Psychotic Disorders;   Schizophrenia;   Schizoaffective Disorder;   Delusional Disorder;   Schizophreniform Disorder
Intervention: Behavioral: modified cognitive behavioural therapy (mCBT)
Outcome Measures: PANSS positive syndrome (sum of items P1-P7), assessed during the treatment phase (9 month) monthly and during the follow-up phase (2 years) every 6 months;   additional symptom ratings (PSYRATS);   social functioning (GAF);   illness related events (suicide, suicide attempts, rehospitalisation, severe depressive symptom exacerbation);   quality of life (MSLQ)assessed monthly during the treatment phase (9 months) and every 6 months during the follow-up phase (2 years)
7 Recruiting Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism.
Condition: Delusion of Reference
Interventions: Dietary Supplement: Endocrine Society Upper Limit Dosage Vitamin D;   Dietary Supplement: Institute of Medicine (IOM) Dosage Vitamin D;   Dietary Supplement: Calcium
Outcome Measures: Compare the effects of 10000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on incidence of hypercalciuria (spot urine calcium:creatinine ratio, 24-hour urine calcium).;   Compare the effects of 10,000 IU/day vitamin D plus 2,000 mg/day calcium versus 600 IU/day vitamin D plus 2,000 mg/day calcium on vitamin D metabolism [25(OH)D, 1,25(OH)2D], and bone turnover.
8 Recruiting Contrasting Group Therapy Methods for Psychosis
Conditions: Psychosis;   Schizophrenia;   Schizoaffective Disorder;   Schizophreniform Disorder
Interventions: Behavioral: Metacognitive Training (MCT);   Behavioral: Cognitive Remediation (CR)
Outcome Measures: Delusion Severity;   Symptom Ratings;   Cognitive Function;   Cognitive Bias;   Insight;   Social cognition;   Social Cognition;   Psychosocial/Everyday Functioning;   Feasibility and acceptability
9 Unknown  Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
Conditions: Schizophrenia;   Schizoaffective Disorder;   Delusional Disorder
Outcome Measure:
10 Recruiting Integrated Care in Psychosis
Conditions: Schizophrenia;   Schizophreniform Disorder;   Schizoaffective Disorder;   Delusional Disorder;   Psychotic Disorder NOS;   Bipolar Disorder;   Severe Major Depression With Psychotic Features
Intervention: Other: Integrated care
Outcome Measures: Time to service disengagement;   Change of functioning as measured with the Global Assessment of Functioning Scale (GAF);   Change of quality of life as measured with the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-18);   Change of psychopathology as measured with the Brief Psychiatric Rating Scale (BPRS);   Change of satisfaction with care as measured with the Client Satisfaction Questionnaire (CSQ-8);   Service use data
11 Unknown  Cognitive Determinants of Psychoeducation and Information in Psychoses
Conditions: Schizophrenia;   Delusional Disorders (ICD-10)
Intervention: Behavioral: COGPACK training, psychoeducation
Outcome Measures: illness knowledge, adherence to treatment, insight to the illness, satisfaction with treatment. 9-month follow-up: number of rehospitalizations, days in hospital;   Psychopathological status;   Psychosocial rehabilitation
12 Recruiting Feeling of Being in Control of One's Own Action
Conditions: Schizophrenia;   Bipolar Disorders
Intervention: Behavioral: Experimental psychology methods (computer tests)
Outcome Measure:
13 Recruiting Improving Work Outcome for People With Severe Mental Illness
Conditions: Schizophrenia, Schizotypal and Delusional Disorders;   Bipolar Affective Disorder;   Recurrent Depressive Disorder
Interventions: Behavioral: Individual Placement and support (IPS);   Behavioral: IPS plus
Outcome Measures: Hours in competitive employment or education;   In competitive employment or education at some point during follow up period;   Days to first employment or beginning of education;   Average monthly earnings in follow-up period;   Hours of work per week among those who obtain competitive employment during the follow-up period;   Negative symptoms measured with Schedule for assessment of negative symptoms in schizophrenia (SANS);   Cognitive functions measured with The Brief Assessment of Cognition in Schizophrenia (BAC);   Functioning measured with Global Assessment of Functioning (GAF);   Functioning measured with Personal and Social Performance (PSP);   Quality of life measured with SF-12;   Empowerment measured with Empowerment Scale;   Self-efficacy measured with General self-efficacy scale (GSE);   Self-esteem measured with The Rosenberg Self-Esteem scale
14 Recruiting Understanding Hallucinations (Part I)
Conditions: Hallucinations;   No Hallucinations
Outcome Measures: The number of clusters of patients with shared symptom profiles as determined by latent class analysis, and the difference in scores on cognitive assessment between these identified clusters.;   The internal consistency, test-retest reliability, inter-rater reliability, criterion validity and construct validity of a newly developed questionnaire.;   The difference in scores on cognitive assessment between participant groups with and without psychotic symptoms.
15 Recruiting Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
Conditions: Schizoaffective Disorder;   Schizophrenia
Outcome Measure: Regional binding potentials of [11C]NNC-112 and [18F]Fallypride
16 Recruiting Remote Cognitive Remediation
Conditions: Schizophrenia;   Bipolar Disorder With Psychosis
Interventions: Behavioral: Cognitive Remediation;   Behavioral: Sham Cognitive Remediation
Outcome Measures: Neurocognitive composite score;   Functional Capacity
17 Not yet recruiting Treatment of Psychosis and Agitation in Alzheimer's Disease
Conditions: Alzheimer's Disease;   Psychosis;   Agitation
Interventions: Drug: Lithium;   Drug: Placebo
Outcome Measures: Change in Neuropsychiatric Inventory (NPI) Score;   Clinical Global Impression (CGI) Global;   Clinical Global Impression (CGI) Behavior;   Young Mania Rating Scale;   Treatment Emergent Signs and Symptoms (TESS);   Simpson-Angus Scale;   Basic Activities of Daily Living (BADL);   Zarit Caregiver Burden Interview;   Clinical Dementia Rating Scale (CDR)
18 Recruiting Genetic Study of Schizophrenia
Conditions: Psychotic Disorder;   Schizoaffective Disorder;   Schizophrenia
Outcome Measure:
19 Recruiting Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
Condition: Smoking Cessation
Interventions: Drug: Placebo;   Drug: varenicline tartrate;   Drug: bupropion hydrochloride;   Drug: Nicotine Replacement Therapy Patch
Outcome Measures: At least 1 severe AE of anxiety depression, feeling abnormal, or hostility and/or moderate or severe AE of: agitation, aggression, Delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation/behavior/completed;   4 week Carbon Monoxide (CO) confirmed continuous abstinence for Weeks 9 through 12.;   Carbon Monoxide (CO) confirmed continuous abstinence from Week 9 through Week 24;   The presence or absence of each component comprising the primary neuropsychiatric adverse event endpoint.;   Individual item responses and overall scores for Hospital Anxiety and Depression Scale;   Individual item responses and overall scores for Columbia Suicide Severity Rating Scale;   Individual item responses and overall scores for Global Clinical Impression of Improvement
20 Recruiting Cross-Sectional Iloperidone IVGTT
Conditions: Schizophrenia;   Serious Mental Illness;   Metabolic Syndrome;   Insulin Resistance;   Glucose Metabolism
Outcome Measures: Difference between cohorts in glucose metabolism;   Difference between cohorts in triglycerides;   Difference between cohorts on LDL cholesterol